Novo Nordisk raised its full-year 2026 outlook on November 4 after sales of its Wegovy weight-loss pill exceeded analysts’ expectations in the third quarter. Reuters reported that pill sales reached 5.39 billion Danish crowns, above the 4.62 billion forecast cited by analysts.
The update is important for the competitive landscape in obesity medicines. Investors are watching how oral treatments, injectable products, pricing and access influence demand in the United States and international markets.
Novo said it now expects adjusted sales and operating profit for 2026 to range from 2% growth to a 2% decline at constant exchange rates, an improvement on its previous outlook. The company’s forecast remains subject to market conditions, competition and reimbursement dynamics.
The results do not settle the longer-term contest in the obesity-drug market. Supply, clinical outcomes, affordability and the ability to reach new patient groups will remain important factors.
Source: Reuters, November 4, 2026 — https://www.reuters.com/business/novo-nordisk-q3-profit-beats-forecast-raises-2026-guidance-2026-11-04/
